Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

Mahesh Parmar, Jonathan A. Ledermann, Nicoletta Colombo et al. · The Lancet · 2003 · 1.2K citations

Medicine, Gynecology, Oncology +17

Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

Jacobus Pfisterer, Marie Plante, Ignace Vergote et al. · Journal of Clinical Oncology · 2006 · 751 citations · Full text

Medicine, Oncology, Pharmacology +17

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

Éric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist et al. · Journal of Clinical Oncology · 2010 · 572 citations

Medicine, Oncology, Pharmacology +17

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

Alan N. Gordon, Margaret Tonda, Steven Sun et al. · Gynecologic Oncology · 2004 · 431 citations

Medicine, Oncology, Pharmacology +17

Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial

Philipp Harter, Andreas du Bois, Maik Hahmann et al. · Annals of Surgical Oncology · 2006 · 422 citations

Medicine, Oncology, Surgery +16